• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Type 2 Diabetes: After the Diagnosis, Resist Inertia

News
Slideshow

Diabetes is a progressive disease and takes advantage of inaction. How would you manage our patient Mrs Davis?

After a diagnosis of type 2 diabetes, clinician and patient alike are challenged to keep pace with and, ideally stay ahead of, the progressive ß-cell deterioration that underlies diabetes pathophysiology. Find out how Mrs Davis and her doctor get started.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Grace Halsey
October 27th 2025
Article

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose / Image credit: ©New Africa/AdobeStock

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose

Sydney Jennings
October 16th 2025
Article

Your daily dose of the clinical news you may have missed.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials / image credit ©MichaelVi/stock.adobe.com

Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials

Grace Halsey
October 15th 2025
Article

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents

FDA Accepts MannKind sBLA for Inhaled Insulin for Children and Adolescents with Diabetes

Grace Halsey
October 13th 2025
Article

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

© 2025 MJH Life Sciences

All rights reserved.